Zepbound and Wegovy are approved for weight loss and weight management, while Mounjaro is not. But doctors may prescribe Mounjaro off-label for this purpose. (Off-label use means a drug is ...

Lilly dominates GLP-1 market but faces near-term headwinds, while AstraZeneca boasts steady growth, rising estimates and a higher dividend yield.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

The drug can also be prescribed off-label for weight loss ... Another drug called Zepbound contains the same active ingredient as Mounjaro and is FDA approved for weight loss.

If fillers are about retaining youth, Ozempic is about nailing the metabolism — with needles doing the heavy lifting ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the ...

Insulin efsitora alfa (investigational once-weekly basal insulin): In another ADA-sponsored symposium, Lilly will share results from the QWINT-1, QWINT-3 and QWINT-4 Phase 3 trials, which evaluated ...

Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro.